Physician profile

Hamed Khosravi

Hematology & Oncology · Woodbridge, VA

NPI 1407802671

$16,175.05

in general payments reported to CMS, 2019-2025

80 companies · $2,639 in 2025

The $2,639 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$7,513.57
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$1,975.00
Travel and Lodging$997.98
Long Term Medical Supply Or Device Loan$299.10
Education$262.86

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Exelixis INC. $3,325.86 2019-2025 Cabometyx
Novartis Pharmaceuticals Corporation $1,656.70 2019-2025
Janssen Biotech, INC. $1,302.60 2019-2025 Tecvayli, Erleada, Darzalex
Pfizer INC. $656.41 2019-2025
Emd Serono, INC. $580.68 2019-2023 Tepmetko
Merck Sharp & Dohme LLC $514.86 2019-2025 Keytruda, Lynparza
Genentech USA, INC. $467.22 2019-2025 Tecentriq, Venclexta, Polivy
Abbvie INC. $455.55 2019-2025
Astrazeneca Pharmaceuticals Lp $436.19 2019-2025 Enhertu, Imfinzi
E.R. Squibb & Sons, L.L.C. $384.10 2019-2025 Opdivo, Eliquis
Daiichi Sankyo INC. $366.76 2019-2025 Enhertu, Injectafer, Datroway
Eisai INC. $332.62 2019-2025
Amgen INC. $309.88 2019-2024 Kyprolis, Lumakras, Prolia
Takeda Pharmaceuticals U.S.A., INC. $294.19 2019-2025 Ninlaro, Iclusig
Horizon Therapeutics Plc $223.51 2019-2023 Krystexxa, Tepezza
Show all 80 companies
CompanyGeneral paymentsYearsTop products
Celgene Corporation $217.99 2020-2024 Pomalyst
Beigene USA, INC. $213.22 2020-2025 Brukinsa
Incyte Corporation $212.53 2020-2025 Jakafi, Monjuvi, Pemazyre
Pharmacyclics LLC, An Abbvie Company $201.91 2019-2023 Imbruvica
Astellas Pharma US INC $191.58 2020-2025 Xtandi, Xospata, Padcev
Kite Pharma, INC. $187.64 2020-2023 Yescarta
Genzyme Corporation $181.90 2019-2025
Servier Pharmaceuticals LLC $175.46 2022-2025
Gilead Sciences, INC. $170.75 2019-2025 Trodelvy
Coherus Oncology, INC. $168.47 2022-2025 Udenyca, Loqtorzi
Spectrum Pharmaceuticals INC. $156.65 2023-2025 Rolvedon
Myriad Genetic Laboratories, INC. $134.29 2022-2025 Myrisk
Array Biopharma INC $132.18 2021-2025 Lorbrena, Braftovi, Mektovi
Regeneron Healthcare Solutions, INC. $131.38 2023-2025 Libtayo
Lilly USA, LLC $124.68 2019-2023 Verzenio, Retevmo, Jaypirca
Alexion Pharmaceuticals, INC. $108.95 2019-2024 Ultomiris
Pharmacosmos Therapeutics INC. $105.10 2023-2025 Monoferric
Clovis Oncology, INC. $101.00 2019-2020
Mirati Therapeutics, INC. $94.54 2023 Krazati
Taiho Oncology, INC. $87.82 2023
Tg Therapeutics, INC. $87.68 2022
Genmab U.S., INC. $85.99 2023-2024 Epkinly
Puma Biotechnology, INC. $85.87 2020-2025
Sobi, INC $84.49 2025
Dendreon Pharmaceuticals LLC $79.24 2019-2025 Provenge
Adaptive Biotechnologies Corporation $77.44 2022-2025 Clonoseq
Pharmaessentia USA Corporation $67.71 2023 Besremi
Sumitomo Pharma America, INC. $64.66 2024 Orgovyx
G1 Therapeutics, INC. $63.36 2022-2023 Cosela
Ipsen Biopharmaceuticals, INC $58.66 2023-2024 Somatuline Depot, Onivyde, Tazverik
Amneal Pharmaceuticals LLC $58.60 2023-2025 Alymsys, Avastin
Janssen Pharmaceuticals, INC $50.80 2020-2023 Xarelto
Glaxosmithkline, LLC. $47.67 2022-2024 Ojjaara
Tersera Therapeutics LLC $47.38 2024-2025 Quzyttir
Boehringer Ingelheim Pharmaceuticals, INC. $45.78 2019-2024
Rigel Pharmaceuticals, INC. $45.48 2020-2023 Rezlidhia, Tavalisse
Seagen INC. $44.53 2021-2022
Sirtex Medical INC $43.58 2019-2020
Bayer Healthcare Pharmaceuticals INC. $43.58 2021-2023
Lundbeck LLC $38.86 2021-2022
Deciphera Pharmaceuticals INC. $38.53 2021-2023 Qinlock
Partner Therapeutics, INC. $36.18 2019
Alnylam Pharmaceuticals INC. $35.25 2023-2025 Givlaari
Stemline Therapeutics INC. $28.61 2023 Orserdu
Azurity Pharmaceuticals, INC. $24.81 2025 Danziten
Pharmaand Gmbh $24.70 2025 Rubraca
Tolmar, INC. $24.70 2025 Rubraca, Eligard
Accord Healthcare, INC. $23.62 2025
Celltrion USA INC. $23.20 2024 Vegzelma
Boston Scientific Corporation $23.01 2019
Tempus Ai, INC $21.83 2025 Xt Cdx
Beone Medicines USA, INC. $21.67 2025 Brukinsa, Tevimbra
Novocure INC. $21.19 2025 Optune Lua (Novottf-200t)
Morphosys, US INC. $21.11 2023 Monjuvi
Blueprint Medicines Corporation $20.12 2022
Sandoz INC. $20.11 2025 Zarxio
Foundation Medicine, INC. $17.44 2023
Medtronic, INC. $17.10 2023 Intellis Adaptivestim
Zydus Pharmaceuticals (USA) INC. $16.90 2025
Amag Pharmaceuticals, INC. $16.29 2019
Heron Therapeutics, INC. $15.56 2019
Sun Pharmaceutical Industries INC. $14.67 2019
Cti Biopharma Corp. $14.34 2023 Vonjo
Secura Bio, INC. $13.96 2019
Adc Therapeutics America, INC. $13.62 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Hamed Khosravi

$16,175.05

in general payments reported 2019-2025

Years
2019-2025
Top company
Exelixis INC.
Context
The $2,639 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).

https://glasscript.com/doctor/17594/hamed-khosravi

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.